GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ENDRA Life Sciences Inc (NAS:NDRA) » Definitions » Cyclically Adjusted Price-to-FCF

ENDRA Life Sciences (ENDRA Life Sciences) Cyclically Adjusted Price-to-FCF : (As of May. 18, 2024)


View and export this data going back to 2017. Start your Free Trial

What is ENDRA Life Sciences Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


ENDRA Life Sciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for ENDRA Life Sciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ENDRA Life Sciences Cyclically Adjusted Price-to-FCF Chart

ENDRA Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ENDRA Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ENDRA Life Sciences's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, ENDRA Life Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ENDRA Life Sciences's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ENDRA Life Sciences's Cyclically Adjusted Price-to-FCF falls into.



ENDRA Life Sciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

ENDRA Life Sciences's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec23 is calculated as:

For example, ENDRA Life Sciences's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec23 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=-1.506/129.4194*129.4194
=-1.506

Current CPI (Dec23) = 129.4194.

ENDRA Life Sciences Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 -52.250 99.070 -68.257
201512 -29.606 99.792 -38.396
201612 -25.804 101.863 -32.785
201712 -23.978 104.011 -29.835
201812 -34.676 105.998 -42.338
201912 -23.021 108.420 -27.480
202012 -11.273 109.897 -13.276
202112 -5.458 117.630 -6.005
202212 -4.487 125.222 -4.637
202312 -1.506 129.419 -1.506

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ENDRA Life Sciences  (NAS:NDRA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


ENDRA Life Sciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of ENDRA Life Sciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ENDRA Life Sciences (ENDRA Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
3600 Green Court, Suite 350, Ann Arbor, MI, USA, 48105-1570
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Executives
Michael Milos Thornton officer: Chief Technology Officer 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Anthony Digiandomenico director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Alexander Y Tokman director C/O MICROVISION, INC., 6222 185TH AVENUE NE, REDMOND WA 98052
Francois Roger Michelon director, officer: Chief Executive Officer 430 N. JUNO LANE, JUNO BEACH FL 33406
Lou Basenese director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Irina Pestrikova officer: Senior Director, Finance 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Renaud Bertrand Maloberti officer: Chief Commercial Officer 10 ACORN WAY, GEORGETOWN MA 01833
David R. Wells officer: Chief Financial Officer 2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Michael Harsh director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Longboard Capital Advisors, Llc 10 percent owner 9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad 10 percent owner 1312 CEDAR ST., SANTA MONICA CA 90405
Sanjiv Sam Gambhir director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105